Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) was the target of a significant growth in short interest during the month of April. As of April 28th, there was short interest totalling 6,683,963 shares, a growth of 1.0% from the April 13th total of 6,620,845 shares. Based on an average trading volume of 799,776 shares, the short-interest ratio is currently 8.4 days.

In related news, insider Barbara White bought 4,233 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The shares were acquired at an average cost of $9.49 per share, with a total value of $40,171.17. Following the completion of the transaction, the insider now owns 166,300 shares of the company’s stock, valued at $1,578,187. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders purchased 18,618 shares of company stock worth $135,080 over the last three months. Corporate insiders own 11.60% of the company’s stock.

A number of large investors have recently made changes to their positions in CRBP. Milestone Group Inc. bought a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth about $102,000. IPG Investment Advisors LLC bought a new stake in shares of Corbus Pharmaceuticals Holdings during the first quarter worth about $109,000. Quantbot Technologies LP bought a new stake in shares of Corbus Pharmaceuticals Holdings during the first quarter worth about $114,000. Bainco International Investors bought a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth about $136,000. Finally, SG Americas Securities LLC bought a new stake in shares of Corbus Pharmaceuticals Holdings during the first quarter worth about $148,000. 25.91% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 1.5488% during mid-day trading on Monday, hitting $6.3501. 231,769 shares of the stock were exchanged. The stock’s market cap is $318.89 million. Corbus Pharmaceuticals Holdings has a 52 week low of $2.38 and a 52 week high of $10.78. The company has a 50 day moving average price of $6.79 and a 200 day moving average price of $7.63.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $1.29 million during the quarter, compared to analysts’ expectations of $2.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 128.85% and a negative net margin of 785.22%. Analysts expect that Corbus Pharmaceuticals Holdings will post ($0.77) EPS for the current fiscal year.

A number of research analysts have weighed in on the stock. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Sunday, May 14th. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research report on Tuesday, May 9th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $27.00 price target (up from $20.00) on shares of Corbus Pharmaceuticals Holdings in a research report on Monday, April 3rd.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/22/corbus-pharmaceuticals-holdings-inc-crbp-short-interest-update.html.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

12 Month Chart for NASDAQ:CRBP

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.